Opioid

BioXcel Therapeutics Inc (NASDAQ: BTAI) has announced topline results from its Phase 1b/2 proof-of-concept RELEASE study evaluating BXCL501 for the treatment of opioid withdrawal symptoms. BXCL501 is the Company's proprietary, orally dissolving thin film formulation of...

In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...

This article was originally published on Microdose Psychedelic Insights, and appears here with permission. Canada’s health minister, Patty Hajdu, is appealing to the government of Alberta to keep their injectable opioid agonist treatment program open. The controversial, yet...

October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500's 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA...

Shares of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) soared higher by 60 percent early Monday morning in reaction to a new partnership with Novartis AG (ADR) (NYSE: NVS). What Happened Adamis, a specialty biopharmaceutical company that focuses on treatments for respiratory diseases and...

President Donald Trump in March said he was considering suing drug companies fueling the opioid crisis — and Congress will allocate $6 billion in new funding over the next two years to advance the fight. The strategy, coupled with other policies, could bode well for Recro Pharma Inc (...

Insys Therapeutics Inc (NASDAQ: INSY), a pharmaceutical company that focuses on a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients called Subsys, reported its fourth quarter results Thursday which prompted Piper Jaffray to downgrade the stock. The Analyst...

Shares of Insys Therapeutics Inc (NASDAQ: INSY) plummeted as low as $4.10 Tuesday morning as the company faces a notable legal battle concerning its founder John Kapoor. Kapoor resigned from Insys' board of directors over the weekend after he was arrested last week. The executive is said to...

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) spiked 46 percent Thursday when President Donald Trump declared a crackdown on opioid abuse. “We’re going to be spending lots of money on coming up with a non-addictive solutions,” Trump said during a press conference. The company develops...

President Donald Trump catalyzed a selloff in opioid-exposed stocks Thursday as he declared the national epidemic a public health emergency and renewed the government’s crackdown on fentanyl. “I will be pushing the concept of non addictive painkillers very, very hard,” Trump said...

On the same day President Donald Trump was expected to declare the national opioid epidemic a public health emergency, a Boston Federal Court charged John Kapoor, former CEO and chairman of the opioid producing Insys Therapeutics Inc (NASDAQ: INSY), along with six other executives with a...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) peaked north of $250 per share in 2015, but by 2017 they dropped to a single digit. Needless to say, this represented a challenging time for the company.   But since bottoming at $8.31 per share this year, the company has made "great...

Versión en Español en El Planteo: La Marihuana Podría Ayudar a Tratar Adicciones a las Drogas y el Alcohol People often talk about marijuana as an alternative to opioids and as a treatment for numerous addictions like alcohol and tobacco. But, like most praises (and...

The U.S. Food and Drug Administration's quest to address the growing opioid crisis is hurting many pharmaceutical companies, including Endo International plc - Ordinary Shares (NASDAQ: ENDP), presenting an opportunity for companies like Alkermes Plc (NASDAQ: ALKS), which makes treatments for opioid...

Shares of Endo International plc - Ordinary Shares (NASDAQ: ENDP) were trading lower by more than 10 percent Friday morning in reaction to the U.S. Food and Drug Administration's request for the company to withdraw from the market its opioid painkiller called Opana ER. Stifel's Annabel Samimy felt...